Emerging incidence trends of eosinophilic esophagitis over 25 years: Results of a nationwide register-based pathology cohort
- PMID: 33426755
- PMCID: PMC8365671
- DOI: 10.1111/nmo.14072
Emerging incidence trends of eosinophilic esophagitis over 25 years: Results of a nationwide register-based pathology cohort
Abstract
Rationale: Eosinophilic esophagitis (EoE) has emerged from a case-reportable illness in the early 1990s to a distinct clinicopathological entity. Increasing worldwide incidences have been observed, although due to various study designs estimates are inconsistent.
Aim: To determine population-based annual incidence rates over a time period of 25 years.
Methods: A nationwide register-based pathology (PALGA) search was performed to identify reports describing esophageal eosinophilia between 1995 and 2019. EoE was identified if the diagnosis was confirmed by the pathologist. Crude incidence rates were estimated by the number of new EoE cases per year and matched with population data.
Results: Between 1995 and 2019, 7361 unique patients' reports mentioned esophageal eosinophilia, of these 4061 were classified as EoE (71% male, mean age 37.9 ± 18.4 years). In total, 639 (16%) children (<18 years) were diagnosed. The EoE incidence increased from 0.01 in 1995 (95% CI: 0.0 - 0.04) to 3.16 (95% CI: 2.90 - 3.44) per 100.000 inhabitants in 2019. EoE was significantly more prevalent in males (OR 2.48 | 95% CI: 2.32 - 2.65; vs. females p < 0.001) and adults (OR 1.42 | 95% CI: 1.31 - 1.55; vs. children p < 0.001). Highest incidences were observed in 2019, being 4.37 (95% CI: 3.94 - 4.84) vs. 1.97 (95% CI: 1.68 - 2.29) per 100.000 males and females, respectively (p < 0.001). No seasonal variation was observed.
Conclusion: Over the past quarter century, the annual rates of newly diagnosed EoE patients raised dramatically and this increase has not reached a deceleration yet.
Keywords: eosinophilic esophagitis; epidemiology; esophageal eosinophilia and allergy; incidence.
© 2021 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Conflict of interest statement
WEdR, MEB, MJW, BDvR, AHB, and JV have no conflicts of interest. AJB has received research funding from Nutricia, SST, Norgine, and Bayer; and speaker and/or consulting fees from Laborie, EsoCap, Medtronic, DrFalk, Calypso, Regeneron, Celgene, Norgine, and AstraZeneca and owns stocks SST.
Figures
References
-
- Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic Esophagitis in Children and Adults: A Systematic Review and Consensus Recommendations for Diagnosis and Treatment. Gastroenterology. 2007;133:1342‐1363. - PubMed
-
- Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3‐20. - PubMed
-
- Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med. 2004;351:940‐941. - PubMed
-
- Attwood S, Smyrk T, Demeester T, Jones J. Esophageal eosinophilia with dysphagia. A distinct clincopathological syndrome. J Dig Dis. 1993;38:109‐116. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
